Terms: = Colorectal cancer AND B2M, P61769, 567, ENSG00000166710 AND Clinical Outcome
4 results:
1. Immune Marker Spatial Distribution and clinical outcome after PD-1 Blockade in Mismatch Repair-deficient, Advanced colorectal Carcinomas.
Saberzadeh-Ardestani B; Graham RP; McMahon S; Ahanonu E; Shi Q; Williams C; Hubbard A; Zhang W; Muranyi A; Yan D; Jin Z; Shanmugam K; Sinicrope FA
Clin Cancer Res; 2023 Oct; 29(20):4268-4277. PubMed ID: 37566222
[TBL] [Abstract] [Full Text] [Related]
2. Favorable long-term clinical outcome of uncovered D-weave stent placement as definitive palliative treatment for malignant colorectal obstruction.
Tominaga K; Maetani I; Sato K; Shigoka H; Omuta S; Ito S; Saigusa Y
Dis Colon Rectum; 2012 Sep; 55(9):983-9. PubMed ID: 22874606
[TBL] [Abstract] [Full Text] [Related]
3. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
Bokemeyer C; Bondarenko I; Hartmann JT; de Braud F; Schuch G; Zubel A; Celik I; Schlichting M; Koralewski P
Ann Oncol; 2011 Jul; 22(7):1535-1546. PubMed ID: 21228335
[TBL] [Abstract] [Full Text] [Related]
4. Cost analysis of transanal endoscopic microsurgery for rectal tumours.
Maslekar S; Pillinger SH; Sharma A; Taylor A; Monson JR
Colorectal Dis; 2007 Mar; 9(3):229-34. PubMed ID: 17298620
[TBL] [Abstract] [Full Text] [Related]
